METHODS	One hundred twelve subjects ages 6-17 years with moderate to severe CD received infliximab induction ( 5 mg/kg/dose ) at weeks 0 , 2 , and 6 ; week-10 responders were randomized to infliximab every 8 or every 12 weeks maintenance therapy .\